NEW YORK (GenomeWeb News) – MDxHealth today said that it has signed a partnership with a subsidiary of Sumitomo to bring the firm's molecular diagnostics products to the Japanese market.

Liege, Belgium-based MDxHealth said that Sumitomo subsidiary Summit Pharmaceuticals International will market its pharmaco molecular diagnostic epigenetic technologies and products. Specifically, Summit will aim to provide companion diagnostics to pharmaceutical firms in the Japanese market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.